Recommendations for observational studies of comorbidity in multiple sclerosis

dc.contributor.authorMarrie, Ruth Ann
dc.contributor.authorMiller, Aaron
dc.contributor.authorSormani, Maria Pia
dc.contributor.authorThompson, Alan
dc.contributor.authorWaubant, Emmanuelle
dc.contributor.authorTrojano, Maria
dc.contributor.authorO'Connor, Paul
dc.contributor.authorFiest, Kirsten
dc.contributor.authorReider, Nadia
dc.contributor.authorReingold, Stephen
dc.contributor.authorCohen, Jeffrey A.
dc.date.accessioned2019-01-24T21:11:55Z
dc.date.available2019-01-24T21:11:55Z
dc.date.issued2016
dc.description.abstractObjective:To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies.Methods:We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity.Results:We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed.Conclusion:Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.
dc.description.grantingagencyNational Multiple Sclerosis Society
dc.description.grantingagencyECTRIMS
dc.description.grantingagencyDon Paty Career Development Award from the MS Society of Canada
dc.description.grantingagencyManitoba Research Chair from Research Manitoba
dc.description.grantingagencyInternational Advisory Committee on Clinical Trials in Multiple Sclerosis
dc.description.grantingagencyEuropean Committee for Treatment and Research in Multiple Sclerosis
dc.description.grantingagencyUS National Multiple Sclerosis Society
dc.identifier.citationMarrie, R. A., Miller, A., Sormani, M. P., Thompson, A., Waubant, E., … Trojano, M. (2016). Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 86(15), 1446–1453. https://doi.org/10.1212/wnl.0000000000002474
dc.identifier.doi10.1212/WNL.0000000000002474
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/35781
dc.identifier.issn0028-3878
dc.identifier.urihttp://hdl.handle.net/1880/109522
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.publisher.departmentCritical Care Medicine
dc.publisher.facultyCumming School of Medicine
dc.publisher.hasversionPublished version
dc.publisher.policyhttp://www.neurology.org/open-access/neuro
dc.rights© 2016 American Academy of Neurology
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectEpidemiology
dc.subjectMedical/Systematic disease
dc.subjectMultiple sclerosis
dc.titleRecommendations for observational studies of comorbidity in multiple sclerosis
dc.typeReview
Files
Original bundle
Now showing 1 - 5 of 8
Loading...
Thumbnail Image
Name:
2016_Recommendations.pdf
Size:
214.06 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Coinvestigators.pdf
Size:
11.88 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Table_e-1.pdf
Size:
150.57 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Table_e-2.pdf
Size:
27.98 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Appendix_e-1.pdf
Size:
21.19 KB
Format:
Adobe Portable Document Format